{
  "source": "PA-Notification-Isturisa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1318-6\nProgram Prior Authorization/Notification\nMedication Isturisa® (osilodrostat)\nP&T Approval Date 6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nIsturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of endogenous\nhypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has\nnot been curative.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Isturisa will be approved based on both of the following criteria:\na. Diagnosis of Cushing’s syndrome\n-AND-\nb. One of the following:\n(1) Patient is not a candidate for pituitary surgery\n-OR-\n(2) Pituitary surgery has not been curative\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Isturisa will be approved based on the following criterion:\na. Documentation of positive response to Isturisa therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply Limits may be in place\n4. References:\n1. Isturisa [Package Insert]. Bridgewater, NJ: Recordati Rare Disease, Inc.; April 2053.\nProgram Prior Authorization/Notification - Isturisa (osilodrostat)\nChange Control\n6/2020 New program\n6/2021 Annual review with no change to coverage criteria.\n6/2022 Annual review with no change to clinical criteria.\n6/2023 Annual review with no change to coverage criteria. Added state\nmandate footnote.\n6/20",
    "nnual review with no change to coverage criteria.\n6/2022 Annual review with no change to clinical criteria.\n6/2023 Annual review with no change to coverage criteria. Added state\nmandate footnote.\n6/2024 Annual review with no change to coverage criteria. Updated reference.\n6/2025 Annual review. Updated nomenclature with no change to clinical\nintent. Update background and reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}